Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?

Minimal change disease (MCD) is a common cause of nephrotic syndrome, and steroid treatment is usually effective at the expense of adverse effects and frequent relapses. Rituximab, a monoclonal antibody against cluster of differentiation (CD)20 B-lymphocytes, leads to depletion of B-cells and has been frequently used to treat relapsing MCD in children. The efficacy of rituximab in treating adult MCD is limited. We report our experience with the use of rituximab for adult biopsy-proven MCD. Our series includes four adult patients (two males and two females), aged 22-80 years, treated with rituximab. All four patients achieved a complete remission with rituximab which lasted from 12 to 19 months. No adverse events from rituximab were observed. This shows the remarkable efficacy of rituximab in the treatment of minimal change disease in adults and may be preferred in patients at high risk for the development of adverse events from corticosteroids.

[1]  B. Rovin,et al.  Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[2]  S. Hidaka,et al.  Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults , 2020, Clinical and Experimental Nephrology.

[3]  D. Roccatello,et al.  Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome , 2018, Oncotarget.

[4]  Jacques P. Brown,et al.  A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy , 2013, Allergy, Asthma & Clinical Immunology.

[5]  H. Tawbi,et al.  Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective , 2012, Critical Care.

[6]  David T Selewski,et al.  Rituximab (Rituxan) , 2010, American Journal of Neuroradiology.

[7]  V. D’Agati,et al.  Adult minimal-change disease: clinical characteristics, treatment, and outcomes. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[8]  G. Remuzzi,et al.  Cellular responses to protein overload: key event in renal disease progression , 2004, Current opinion in nephrology and hypertension.

[9]  J. Bargman.  Management of minimal lesion glomerulonephritis: evidence-based recommendations. , 1999, Kidney international. Supplement.

[10]  J. Cameron,et al.  Adult-onset minimal change nephrotic syndrome: a long-term follow-up. , 1986, Kidney international.

[11]  D. Jayne,et al.  Con: The use of calcineurin inhibitors in the treatment of lupus nephritis. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  A. C. Simões e Silva,et al.  The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies , 2013, Inflammation Research.